Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Shield Technology

This article was originally published in The Tan Sheet

Executive Summary

Company's Chimal Technology Skin Shield and StarLee Skin Shield "do not qualify for evaluation under the ongoing OTC Drug Review," are unapproved new drugs and are misbranded, FDA says in a March 16 warning letter. Labeling indicates the topical products "are intended to form an impervious 'barrier' or 'shield' on the skin," the agency says, adding the products are promoted as comparable to gloves in preventing adverse effects and diseases caused by contact with various substances, and claim to prevent contracting viral diseases such as AIDS. The Tulsa, Okla.-based firm is scheduled to meet with FDA April 18 to discuss the letter. The firm's products are sold through distributors to the medical, food and cosmetic industries

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS091104

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel